IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2474
Positioning
Market Dominance
Manufacturing
Measuring And Control Equipment
$91M
Sujal M. Patel
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$NAUT Nautilus Biotechnology, Inc. | 47 | 31 | 14 | 75 | - | - | -36.5% | -30.7% | - | - | - | - | 0.0% | 19.0x | $91M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Nautilus Biotechnology, Inc. (NAUT) receives a "Reduce" rating with a composite score of 47.1/100. It ranks #2474 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Sujal M. Patel
Chief Executive Officer
Labor Force
130
31
25
22
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for NAUT
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for NAUT.
View All RatingsInsufficient data for Financial Analysis
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 31 | 9 | +22ALPHA |
| MOMENTUM | 75 | 77 | -2NEUTRAL |
| VALUATION | 14 | 3 | +11ALPHA |
| INVESTMENT | 25 | 13 | +12ALPHA |
| STABILITY | 22 | 5 | +17ALPHA |
| SHORT INT | 81 | 91 | -10DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -36.5% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Nautilus Biotechnology, Inc. receives a Reduce rating from our analysis, with a composite score of 47.1/100 and 2 out of 5 stars, ranking #2474 out of 7,333 stocks. NAUT's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
NAUT's quality score of 31/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -36.5% (sector avg: -2.5%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
NAUT registers a value score of just 14/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 2.11x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Nautilus Biotechnology, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -30.7% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
NAUT shows strong momentum characteristics with a score of 75/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth data is not currently available, while a beta of 1.75 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
Nautilus Biotechnology, Inc. registers a low stability score of 22/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.75 and a debt-to-equity ratio of 19.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
NAUT's short interest factor score of 81/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include high market sensitivity (beta: 1.75), elevated leverage (D/E: 19.00x), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $91M, Nautilus Biotechnology, Inc. benefits from the generally lower volatility and deeper liquidity associated with its size class.
Nautilus Biotechnology, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2474 of 7,333 overall (66th percentile). Key comparisons include ROE of -36.5% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While NAUT currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (14) would have the largest impact on the composite score.
ROE 1370% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 9400% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Nautilus Biotechnology, Inc. (NAUT) as a Reduce with a composite score of 47.1/100 at a current price of $2.85. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in momentum (75th percentile) and quality (31th percentile), which together account for the majority of the composite score. Offsetting weakness in value (14th percentile) and stability (22th percentile) tempers our overall conviction. We assign a No Moat rating (28/100), High uncertainty, and Poor capital allocation.
Key items to watch: valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Nautilus Biotechnology, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 47.1/100 places it at rank #2474 in our full 7,333-stock universe. At $91M in market capitalization, Nautilus Biotechnology, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (75th percentile) are constructive regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for Nautilus Biotechnology, Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $2.85, Nautilus Biotechnology, Inc. is trading at a premium to fundamental value. Our value factor score of 14/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 2.1x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
A conservative balance sheet (19% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
Positive momentum (75th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
The Reduce rating (composite 47.1/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Below-average quality (31th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
High beta of 1.75 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
We assign a High uncertainty rating to Nautilus Biotechnology, Inc.. Key risk factors include elevated market sensitivity (beta of 1.75), below-average price stability (22th percentile), weak quality scores (31th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.75); below-average price stability (22th percentile); weak quality scores (31th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 22th percentile and quality factor at the 31th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (19% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Nautilus Biotechnology, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-36.5%), weak asset returns (ROA -30.7%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Nautilus Biotechnology, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Nautilus Biotechnology, Inc. receives a Reduce rating with a composite score of 47.1/100 (rank #2474 of 7,333). Our quantitative framework assigns a No Moat (28/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 33/100.
Our analysis does not support a constructive view on Nautilus Biotechnology, Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Nautilus Biotechnology, Inc. a meaningful economic moat, scoring 28/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and financial resilience (8.8/20). GM N/A vs sector 43%, OM N/A vs sector 1%. Interest coverage N/A. These pillars form the core of Nautilus Biotechnology, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and economic value creation (2.6/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Nautilus Biotechnology, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 31/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -36.5% and ROA of -30.7%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -36.5% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 19%. The sector median D/E is 0%, putting Nautilus Biotechnology, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Elevated short interest (81th percentile) indicates that sophisticated market participants are betting against the stock.
Above 50MA
37.18%
Net New Highs
+51081
Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering single-molecule proteome analysis, today debuted the Voyager™ Platform, which is designed to power the Iterative Mapping of up to 10 billion intact
SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 46th Annual Health Care Conference. Nautilus’ management is scheduled to participate in a fireside chat on Monday, March 2, 2026, at 10:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Monday. Here are some big stocks recording gains in today’s session. Canopy Growth Corporation (NASDAQ: CGC) shares gained 12.5% to $0.9422. ESS Tech, Inc. (NYSE: GWH) shares jumped 10.1% to $1.53. Honeywell International Inc (NASDAQ: HON) entered into a strategic collaboration with ESS Tech to advance technology development and market ...
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private investment positions. Locafy Limited (NASDAQ: LCFY) jumped 89.7% to $13.28 after the company announced an agreement with a U.S.-based media publisher to utilize "Entity-Based" Keystone SEO technology. TRxADE HEALTH, Inc. (NASDAQ: MEDS) gained 66% to $9.15. TRxADE HEALTH announced a 1-for-15 reverse stock split. ShiftPixy, Inc. (NASDAQ: PIXY) shares climbed 65% to $2.1792 after dropping 43% on Wednesday. Root, Inc. (NASDAQ: ROOT) shares jumped 40% to $13.59 following a Wall Street Journal report suggesting the company has received a takeover bid. VCI Global Limited (NASDAQ: VCIG) rose 37% to $6.79. NexImmune, Inc. (NASDAQ: NEXI) climbed 26.4% to $0.33. Barfresh Food Group, Inc. (NASDAQ: BRFH) rose 26.2% to $1.3001. Talaris Therapeutics, Inc. (NASDAQ: TALS) gained 26% to $2.7750 after the company and Tourmaline Bio announced a merger agreement. Edgio, Inc. (NASDAQ: EGIO) rose 20.1% to $0.55. Advanced Emissions Solutions, Inc. (NASDAQ: ADES) gained 18.4% to $1.54 following strong quarterly sales. Better Choice Company Inc. (NYSE: BTTR) climbed 16% to $0.28. Better Choice reported a strategic investment from Alphia of $5 million, establishing a direct manufacturing relationship. Oncolytics Biotech Inc. (NASDAQ: ONCY) gained 15.7% to $2.4999. ToughBuilt Industries, Inc. (NASDAQ: TBLT) surged 15% to $0.2981. ToughBuilt Industries recently announced the pricing of a $4.5 million public offering. Tempo Automation Holdings, Inc. (NASDAQ: TMPO) shares gained 14.5% to $0.4189. Tempo Automation secured $7 million convertible promissory note facility strengthening financial position and providing capital for Optimum acquisition. Sotera Health Company (NASDAQ: SHC) rose 14.4% to $17.16. Sotera Health finalized settlement of ethylene oxide litigation in Illinois. IGM Biosciences, Inc. (NASDAQ:
Nautilus Biotechnology (NAUT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.